Medical Device Insurance: Clinical Trials and 510(k)

A medical device company in active clinical trials is operating in the most under-insured phase of its corporate life. There is no commercial revenue yet. There is no product in commerce. The temptation to defer insurance investment until clearance is real, and many companies act on it.

The exposures during pre-clearance are not theoretical. Subject injury from clinical trial participation, IRB enforcement against the sponsor, FDA pre-market enforcement (improperly classifying a Significant Risk device as Non-Significant Risk, deviating from the protocol, failing to maintain sponsor monitoring), investor and securities exposure when a trial fails, and employment practices claims from a growing pre-revenue team all sit inside the pre-clearance window. The cost to remedy a problem after it surfaces is materially higher than the cost to insure against it.

This walks through the four coverage areas a medical device company needs during clinical trials and 510(k) review, the regulatory framework that shapes coverage requirements, the planning window during 510(k) review that most companies under-use, and the mistakes that show up repeatedly in pre-clearance program reviews.

Why Pre-Clearance Is the Most Under-Insured Phase

Two patterns produce systematic under-insurance during pre-clearance.

The first is revenue-driven thinking. Founders associate insurance with commercial activity. If there is no product in commerce, they reason, there is little to insure. This reasoning ignores that the regulated activity (the clinical trial itself) is the exposure, not the product in commerce.

The second is staging. The transition from clinical-trial operations to commercial operations feels gradual. The 510(k) is filed, the device enters review, clearance arrives, sales begin. In practice the insurance program has to change abruptly at clearance, and the company that did not prepare during the review window ends up rushing the placement under deadline pressure.

The Four Coverage Areas During Pre-Clearance

A pre-clearance medical device program addresses four distinct exposures. Each has a different underwriting process and a different conversion path at clearance.

Clinical Trials Liability

Clinical trials liability is the primary insurance product during this stage. The coverage addresses subject injury and property damage arising from clinical trial participation, including defense costs and any settlements or judgments.

Two components matter and are sometimes confused. Subject injury coverage compensates patients harmed by trial participation, often on a no-fault basis up to a sub-limit per subject. Liability coverage defends the sponsor against negligence claims and indemnifies for resulting judgments. Both should be present, and the wording matters.

IRB requirements are operational. Most IRBs require evidence of clinical trials insurance before approving a protocol. Some hospital systems require named-insured status on the trial policy for sites conducting the trial, which means the certificate of insurance needs to name each participating institution. Failing to anticipate this creates schedule pressure during site startup.

Limits are calibrated to the protocol. Patient population size, indication risk severity, trial duration, and number of participating sites all factor in. Trials in implanted devices, neurological indications, oncology, and pediatric populations carry higher severity than diagnostic or monitoring trials. Some hospital sites impose minimum coverage requirements meaningfully above what a sponsor might initially budget; the trial budget needs to reflect site requirements when the protocol is designed.

The policy is time-bounded. It covers the regulated activity during the trial period and typically sunsets when enrollment closes. Claims that surface after sunset against a policy without proper tail coverage fall outside coverage. Tail planning is a renewal-cycle conversation, not a post-claim one.

D&O for the Pre-Clearance Stage

D&O exposure during pre-clearance is structurally different from D&O at the commercial stage. Risk drivers are investor litigation in failed trials, FDA and FTC pre-market enforcement (improper marketing claims, premature commercial activity, IDE protocol deviation), securities exposure for any company with outside investors, and employment practices as the team scales.

D&O coverage at the pre-clearance stage scales with funding round, board composition, and investor expectations. Pre-revenue companies with all-insider boards can defer broader coverage and start with a Side-A-only binder path, which covers individual director and officer personal liability when the company cannot indemnify. As outside investors enter and the board composition expands, primary and excess layers expand accordingly. Coverage at each stage is calibrated to investor diligence requirements and the regulatory exposure of the specific company.

D&O for medical device companies and other regulated healthcare segments runs meaningfully higher in premium than D&O for unregulated SaaS at equivalent funding stage. The differential reflects actual claim severity in the segment, including regulatory enforcement risk, trial-failure litigation exposure, and the longer claim development timelines typical of FDA-regulated companies.

Deferring D&O until commercial revenue arrives is a structural mistake. Investor litigation, FDA enforcement, and securities exposure all exist during the pre-clearance window.

Pre-Clearance Product Liability

Product liability coverage is often assumed irrelevant before commercialization. This is false in several specific cases.

Investigational devices used under an IDE in IRB-approved studies create product exposure during the trial. Compassionate use and expanded access programs (where an investigational device is provided to patients outside the IDE protocol with FDA authorization) extend the exposure window. Limited pilot deployments under research protocols, partner-site demonstrations, and pre-commercial validation work with reference accounts all create scenarios where the device interacts with patients before formal commercial launch.

Coverage during this period typically takes the form of named-project endorsements on the clinical trials policy, or a limited products coverage layer with specific carve-outs. The endorsement language is what matters. Coverage that contemplates investigational use, compassionate use, and pre-commercial deployment is structurally different from full commercial products liability.

Pre-clearance products coverage usually does not convert to commercial products liability automatically. At clearance, a new commercial products policy gets placed, and the pre-clearance coverage is run-off or tail-out depending on the claim profile of the trial period.

Cyber for Devices With Software Components

Cyber exposure exists during pre-clearance for any device that collects data, has cloud connectivity, includes software components, or interacts with PHI in clinical use.

Section 524B of the FD&C Act applies to “cyber devices” regardless of pre or post-clearance status. Manufacturers planning to submit a 510(k) for a cyber device must include a Security Risk Management Report, a machine-readable Software Bill of Materials, and a Secure Product Development Framework in the submission. The post-market Cybersecurity Management Plan and Coordinated Vulnerability Disclosure procedures need to be operational before commercialization, which means the cybersecurity program is built during pre-clearance.

HIPAA exposure exists when a device interacts with PHI during clinical use. Cyber coverage that contemplates BAA-flowed indemnification is structurally different from generic data breach coverage. IEC 62304 (software lifecycle for medical devices) and the FDA SaMD framework shape both the regulatory submission and the cyber underwriting conversation.

The IDE Framework and Its Insurance Implications

The Investigational Device Exemption framework under 21 CFR Part 812 governs how unapproved medical devices can be used in clinical investigations. It shapes the insurance program in two ways.

First, the Significant Risk versus Non-Significant Risk determination changes the regulatory pathway. The IRB at the lead site reviews the proposed investigation and determines whether the device is SR or NSR. SR devices require an FDA IDE before the trial can begin. NSR devices proceed under IRB oversight only, with sponsors and investigators bound by the abbreviated requirements of 21 CFR 812.2(b). Misclassification (treating an SR device as NSR) is a documented FDA enforcement target and exposes both the sponsor and individual investigators.

Second, the operating requirements during the trial are extensive. 21 CFR Part 812 imposes sponsor monitoring obligations, adverse event reporting timelines, protocol deviation reporting, informed consent under 21 CFR Part 50, and IRB review and continuing review under 21 CFR Part 56. The clinical trials liability program needs to cover the company’s defense against allegations of non-compliance with these requirements, not just patient injury claims.

A February 2026 warning letter against a sponsor for distributing an investigational device for compassionate use without prior FDA approval framed the issue as a sponsor monitoring failure. The exposure profile for sponsors during IDE trials is real, and FDA enforcement is active.

The 510(k) Review Period: What Most Companies Miss

The window between 510(k) submission and clearance is where most pre-clearance companies under-invest in commercial program preparation.

Stated review timelines understate actual elapsed time. The FDA’s MDUFA V performance goal is 95% of 510(k) submissions decided within 90 FDA days. The shared outcome total time to decision target is 285 calendar days. Actual elapsed time averages 140 to 175 days, with 70 to 80 percent of submissions exceeding the 90-day target. CDRH staffing reductions in early 2025 are likely to extend rather than compress these timelines.

During this window, the company is still operating under pre-clearance coverage. Clinical trials liability remains in force if the trial is still active. D&O remains at pre-clearance limits. Products liability, if it exists at all, is in named-project form. The cost of waiting until clearance to restructure is real.

The planning work during the review window includes securing post-clearance D&O capacity with carriers that quote commercial-stage programs, reviewing distribution agreements for indemnification and additional-insured language, structuring the cybersecurity program for ongoing Section 524B post-market obligations, completing QMSR documentation for inspection-readiness at first commercial sale (QMSR effective February 2, 2026), and beginning conversations with the specialty markets that write the commercial-stage program about timing, limits, and structure.

At clearance, the program restructures substantially. Clinical trials liability sunsets. Products liability becomes the primary coverage. Recall coverage enters the program. Cyber and Tech E&O scale to commercial exposure. D&O renegotiates for commercial-stage language. The transition is detailed in the companion piece on insurance at Class II medical device commercialization.

Common Pre-Clearance Founder Mistakes

Six patterns appear repeatedly in pre-clearance program reviews.

Treating clinical trials coverage as if it covers commercial exposure. Clinical trials liability is bounded to the regulated activity of the trial. It does not convert to commercial products liability at clearance.

Deferring D&O until commercial revenue arrives. Investor litigation, FDA and FTC enforcement, securities claims, and employment practices exposure all exist during pre-clearance. Pre-event premium is materially lower than post-event defense cost.

Not anticipating the post-clearance program restructure. Companies that have not prepared during the 510(k) review window face deadline pressure that narrows market options.

Inadequate IRB-required clinical trials limits. Some hospital sites impose minimum coverage requirements meaningfully above what a smaller sponsor might initially budget. Companies that placed a limit calibrated to internal expectations rather than site requirements discover the gap at site startup, which delays enrollment.

Trial-sunset gaps. Clinical trials policies typically end when the trial concludes. Claims that surface after sunset against a policy without proper tail coverage fall outside coverage.

Cyber gaps for devices with software components. A device with a software component does not become a “cyber device” only at clearance. Section 524B applies prospectively to the 510(k) submission for cyber devices, which means the cybersecurity program is operational before clearance.

A Note on Placement

Generalist commercial brokers struggle with pre-clearance medical device programs because each coverage line requires segment-specific underwriting depth. Clinical trials liability is a specialized product written by a small subset of markets. D&O for pre-revenue healthtech companies requires underwriters who understand actual claim severity in this segment, not generalist tech-startup pricing. Named-project product liability for investigational use is a niche product. Cyber for medical devices interacts with Section 524B, IEC 62304, and SaMD framework considerations that generic cyber underwriters do not work with daily.

Pre-binding underwriting conversations matter more in this segment than in most. Specialty markets at this stage want to understand the device, the protocol, the patient population, the post-market plan, and the post-clearance timeline before quoting.

MedTech Coverage works with pre-clearance medical device companies on programs structured around IDE-SR and NSR trial structures, named-project product liability, pre-clearance D&O calibrated to funding stage, and the cybersecurity program required under Section 524B for cyber devices. Coverage is placed through Tower Street Insurance’s appointments with the specialty markets writing this segment.

If a medical device company is operating a clinical trial under IDE, preparing a 510(k) submission, or in 510(k) review awaiting clearance, a structured coverage review identifies the gaps in the current program and the transition planning that should be underway for the post-clearance restructure.